Document:

Exhibit 10.29

 Exhibit 10.29 
 AMENDMENT #1 
 TO THE 

DEFERRED BONUS PLAN FOR 
 EXECUTIVES OF BRYN MAWR BANK CORPORATION 
 (As Amended and Restated
Effective January 1, 2008) 
 THIS AMENDMENT is made this 20th day of December, 2012, by Bryn Mawr Bank Corporation (hereinafter
referred to as the “Corporation”). 
 W I T N E S S E T
H: 
 WHEREAS, the Corporation maintains the Deferred Bonus Plan for Executives of Bryn Mawr Bank Corporation, as last
amended and restated effective January 1, 2008 (the “Plan”); and 
 WHEREAS, the Corporation deems it necessary
and desirable to amend the Plan to change the eligibility standards for participation in the Plan. 
 NOW, THEREFORE, the Plan
is hereby amended by revising 1.11 thereof to read as follows: 
 1.11 “Executive” means an
employee of a Participating Employer who is a member of a select group of management or highly compensated employees and who is eligible to make a deferral election under the Plan. An employee will be eligible to make a deferral election under the
Plan for a Plan Year if his compensation for the prior Plan Year was at least (a) for purposes of the deferral of bonuses awarded with respect to Plan Years prior to 2013, $100,000, and (c) for purposes of the deferral of bonuses awarded
with respect to 2013 and subsequent Plan Years, the maximum amount of compensation which can be taken into account in the administration of tax-qualified plans under Section 401(a)(17) of the Code with respect to such Plan Year (e.g., $255,000
for 2013). For purposes of this section, compensation for the prior Plan Year shall mean the employee’s compensation reported on Form W-2, including the bonus which was payable to the employee in such prior Plan Year, regardless of whether all
or some portion of the bonus was not reported on Form W-2 as a result of being deferred under the Plan. Additionally, the Administrator may designate a newly hired employee of a Participating Employer as an Executive eligible to make a deferral
election during the Plan Year in which he is hired and the following Plan Year, if such employee’s annualized compensation from the Participating Employer at the time of hire is expected to equal or exceed $100,000 or the maximum amount under
Section 401(a)(17) of the Code, as applicable pursuant to clauses (a) and (b) above. 
 IN WITNESS WHEREOF, the
Corporation has caused this amendment to be executed by its duly authorized officers and its corporate seal to be impressed hereon on the date first above written. 
  

							
	ATTEST:	 		 	BRYN MAWR BANK CORPORATION
				
	 /s/ Diane McDonald
	 		 	By:	 	 /s/ Geoffrey L. HalberstadtExhibit 10.30

 Exhibit 10.30 
 AMENDMENT #2 
 TO THE 

DEFERRED BONUS PLAN FOR 
 EXECUTIVES OF BRYN MAWR BANK CORPORATION 
 (As Amended and Restated
Effective January 1, 2008) 
 THIS AMENDMENT is made this 20th day of December, 2012, by Bryn Mawr Bank Corporation
(hereinafter referred to as the “Corporation”). 
 W I T N E S S
E T H: 
 WHEREAS, the Corporation maintains the Deferred Bonus Plan for Executives of Bryn Mawr Bank
Corporation, as last amended and restated effective January 1, 2008 (the “Plan”); and 
 WHEREAS, the Corporation
deems it necessary and desirable to amend the Plan to enable the Administrator, in its discretion, to terminate a Participant’s interest in the Plan by making a single, lump sum distribution of the entire value of the Participant’s
Account. 
 NOW, THEREFORE, the Plan is hereby amended by revising Article V thereof by adding a new Section 5.4 to read as
follows, provided that this Amendment shall not be effective with respect to any Participant who has an Account balance under the Plan as of the date of this Amendment: 

5.4 Small Cash-Outs. Effective January 1, 2013, and notwithstanding any other provision of this Plan or any
election made hereunder, the Administrator, in its discretion, may direct that a Participant’s entire Account balance, plus the amount standing to the credit of the Participant under any other plans, agreements, methods, programs or other
arrangements with respect to which deferrals of compensation are treated as having been deferred under a single plan under Treasury Regulation Section 1.409A-1(c)(2), be distributed to him or her in a single lump sum, provided that the amount
of such distribution does not exceed the applicable dollar amount under Section 402(g)(1)(B) of the Code (e.g., $17,500 for 2013) . 
 IN WITNESS WHEREOF, the Corporation has caused this amendment to be executed by its duly authorized officers and its corporate seal to be impressed hereon on the date first above written. 

 

							
	ATTEST:	 		 	BRYN MAWR BANK CORPORATION
				
	 Diane McDonald
	 		 	By:	 	 /s/ Geoffrey L. Halberstadt

  

									
	I hereby consent to the application of this Amendment.	  	
				
	Participant Name:	 	  
	  		  	

									
					
	  
	 		 	  
	  		  	

									
	Signature                    	 		  	  dateEX-10.31

 Exhibit 10.31 
 Exhibit B 
 THIS Exhibit B is made and entered into pursuant to the Consulting Agreement by
and between OXiGENE, Inc. (hereinafter referred to as “OXiGENE”) and David Chaplin, Ph.D. (the, “CONSULTANT”) dated the 23rd day of January 2013 (the “Agreement”), and is effective as of the date last signed below (the
“Exhibit Effective Date”). Capitalized terms used in this Exhibit and not otherwise defined will have the same meaning as set forth in the Agreement. 
 1. Exhibit. This document constitutes an Exhibit as defined in the Agreement and the Services to be provided hereunder are subject to the terms and conditions of the Agreement. 

2. Services. CONSULTANT agrees to provide the following consulting Services upon OXiGENE’s request: 

 

	 	•	 	 Attend and/or deliver technical or business presentations on behalf of OXiGENE; and 

 

	 	•	 	 Assist with such project based assignments as may be mutually agreed upon in writing with OXiGENE from time to time. 

OXiGENE and CONSULTANT hereby agree that this Exhibit B is not intended to reduce, enlarge or otherwise alter the scope of CONSULTANT’s
responsibilities to OXiGENE as a member of its Board of Directors or as a consultant providing Services under Exhibit A to the Agreement. 
 3. Compensation. CONSULTANT will provide to OXiGENE invoices for Services rendered as requested hereunder. As full compensation for Services provided hereunder, OXiGENE will pay to CONSULTANT for
the duration of this Exhibit a fee of three hundred seventy-five US Dollars ($375) per hour (travel time to be billed at 50% of Consultant’s hourly rate), not to exceed a daily rate of three thousand U.S. Dollars ($3,000), which assumes eight
(8) or more hours of service within the course of one day. Maximum remuneration for Services performed on a time and materials basis under this Exhibit B, inclusive of travel, living and out of pocket expenses, shall not exceed the amount set
forth in OXiGENE Purchase Order Number [            ], as may be amended from time to time by OXiGENE in its sole discretion; provided however, that in no event shall the total compensation
payable to Consulting in any calendar year exceed the aggregate amount authorized under the Agreement. The Parties agree that Services performed and travel, living and out of pocket expenses incurred by Consultant beyond such maximum remuneration
shall not be subject to payment without the prior written consent of OXiGENE. 
 4. Invoices. Payment of invoices submitted with the
required detail, delineated herein, will be made within thirty (30) days of OXiGENE’s receipt of such invoice. Should any 

  
 1 

 
part of the invoice be in dispute, OXiGENE shall pay the remainder of the undisputed amount according to the terms and conditions described herein while said dispute is being resolved.

 All invoices must be issued to: “OXiGENE, Inc., Attn: Accounts Payable, 701 Gateway Blvd., South San Francisco, CA 94080” and
forwarded via e-mail to ap@oxigene.com for payment. 
 To avoid any delay in payment, all invoices should clearly contain the detail
required by OXiGENE, including: 
 Consultant’s name & full mailing address 

Name the check shall be payable to and the corresponding Tax ID # if applicable 
 Invoice date 
 Total amount due & payment currency 

Description of services rendered/project and/or study number and/or period ending 
 Invoices which do not contain the required detail will be rejected and must be resubmitted in order to be processed and paid. 

-Remainder of Page Left Blank- 

  
 2 

 The parties have indicated their acceptance of the terms of this Agreement by the signatures set forth
below. Each individual signing on behalf of a corporate entity hereby personally represents and warrants his or her legal authority to legally bind that entity. 
  

									
	OXiGENE, INC.	 		 	CONSULTANT
					
	By:	 	 /s/ Peter J. Langecker
	 		 	By:	 	 /s/ David Chaplin

			
	Print Name: Peter J. Langecker, M.D., Ph.D.	 		 	Print Name: David Chaplin, Ph.D.
					
	Date:	 	 27 Feb 2013
	 		 	Date:	 	 Feb 27 2013

  
 3EX-10.20

 EXHIBIT 10.20 
 December 10, 2012 
 Mr. Steven Gatoff 

Dear Steven: 
 This letter agreement (the
“Agreement”) sets forth the terms of your transition from iPass Inc. (the “Company”). 
 1.
SEPARATION DATE. You voluntarily resigned from your position as Senior Vice President and Chief Financial Officer at the Company, effective as of February 22, 2013 (the “Separation Date”). From
the date of this Agreement through the Separation Date (the “Transition Period”), you will continue to use your best efforts to perform your assigned job duties and you will continue to abide by all Company policies and procedures.

 2. TRANSITION BENEFITS. If you timely sign and abide by the terms of this Agreement, and
allow the releases contained herein to become effective, the Company will provide you the following transition benefits: 

(a) Bonus Payment. Although you are not entitled to any bonus for 2013, the Company will pay you an amount equal to your target
bonus for Q1 2013 (the “Bonus Payment”). The total amount of the Bonus Payment will be $28,750.00, subject to standard payroll deductions and withholdings. The Bonus Payment will be paid to you in a lump sum on the first regular
Company payday at least ten (10) days following the Separation Date. 
 (b) Accelerated Vesting of Restricted Stock.
During 2011, you were granted shares of the Company’s restricted stock, which vest, and the shares are released to you, over time as set forth in the governing restricted stock grant notice and the related notice of grant of award and award
agreement (collectively, the “Restricted Stock Agreements”). As part of your transition benefits, the Company will accelerate the vesting of fifteen thousand (15,000) shares from this 2011 restricted stock grant such that you will be
provided with these shares on your Separation Date. Except as modified in this Section 2(b), these shares of restricted stock shall continue to be governed by the terms of the Restricted Stock Agreements. 

(c) Extended Exercise Period of Vested Options. During your employment, you were granted certain options to purchase the
Company’s common stock. Vesting of these options shall cease on your Separation Date. However, as part of this Agreement, the Company will extend the period for you to exercise any options vested as of the Separation Date until
November 22, 2013, or the expiration date of the option, whichever comes first. Except as expressly modified in this Section 2(c), your stock options shall continue to be governed by the applicable grant notice, option agreement, and
governing stock option plan. 
 3. OTHER COMPENSATION OR
BENEFITS. You acknowledge that, except as expressly provided in this Agreement, you will not receive any additional compensation, severance, or benefits after the Separation Date. You further acknowledge and agree that you are not
entitled to receive and will not receive any severance benefits under the terms and conditions of any employment agreement with the Company, any Company severance benefit plan, or any Company change of control severance benefit plan. 

 4. RELEASE OF CLAIMS. 

a. General Release. In exchange for the transition benefits that you are not otherwise entitled to receive, you hereby generally
and completely release the Company and its current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any and all
claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to your signing this Agreement. 

b. Scope of Release. This general release includes, but is not limited to: (a) all claims arising out of or in any way
related to your employment with the Company, or the termination of that employment; (b) all claims related to your 

 
compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other
ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional
distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil
Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended).

 c. ADEA Waiver. You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you may have
under the ADEA (“ADEA Waiver”). You also acknowledge that the consideration given for the ADEA Waiver is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised by this
writing, as required by the ADEA, that: (a) your ADEA Waiver does not apply to any rights or claims that arise after the date you sign this Agreement; (b) you should consult with an attorney prior to signing this Agreement; (c) you
have twenty-one (21) days to consider this Agreement (although you may choose to voluntarily sign it sooner); (d) you have seven (7) days following the date you sign this Agreement to revoke the ADEA Waiver, with such revocation to be
effective only if you deliver written notice of revocation to the Company within the seven (7)-day period; and (e) the ADEA Waiver will not be effective until the date upon which the revocation period has expired unexercised, which will be the
eighth day after you sign this Agreement (“Effective Date”). Nevertheless, your general release of claims, except for the ADEA Waiver, is effective immediately, and not revocable. 

d. Section 1542 Waiver. YOU UNDERSTAND THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS. In giving the
release herein, which includes claims which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code, which reads as follows: “A general release does not extend to
claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” You hereby expressly
waive and relinquish all rights and benefits under that section and any law of any other jurisdiction of similar effect with respect to your release of any unknown or unsuspected claims herein. 

e. Exceptions. Notwithstanding the foregoing, you are not releasing any claim that cannot be waived under applicable state or
federal law. You are not releasing any rights that you have to be indemnified (including any right to reimbursement of expenses) arising under applicable law, the certificate of incorporation or by-laws (or similar constituent documents of the
Company), any indemnification agreement between you and the Company, or any directors’ and officers’ liability insurance policy of the Company. Nothing in this Agreement shall prevent you from filing, cooperating with, or participating in
any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that you acknowledge and agree that you shall not recover any monetary benefits in
connection with any such claim, charge or proceeding with regard to any claim released herein. Nothing in this Agreement shall prevent you from challenging the validity of the release in a legal or administrative proceeding. 

5. GENERAL. This Agreement constitutes the complete, final and exclusive embodiment of the entire agreement between
you and the Company with regard to this subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or
representations. This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This Agreement will be deemed to have been entered into and will be construed and enforced in
accordance with the laws of the State of California as applied to contracts made and to be performed entirely within California. 

 If this Agreement is acceptable to you, please sign below and return the original to me. 

I wish you good luck in your future endeavors. 

Sincerely, 
  

			
	IPASS INC.
		
	By:	 	/s/ J. Michael Badgis
		 	J. Michael Badgis
		 	Vice President of Worldwide Human Resources and Administration
	
	AGREED:
	
	 /s/ Steven Gatoff

	Steven Gatoff
	
	12/10/12
	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]